Urology
Volume 61, Issue 1 , Pages 5-6 , January 2003

Informed consent for prostate-specific antigen testing

  • Peter H Gann

      Affiliations

    • Department of Preventive Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    • Corresponding Author InformationReprint requests: Peter H. Gann, M.D., Department of Preventive Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611, USA

Received 18 July 2002 ,Accepted 13 September 2002.

References 

  1. Etzioni R, Penson DF, Legler JM, et al.  Over diagnosis due to prostate-specific antigen screening (lessons from U.S. prostate cancer incidence trends). J Natl Cancer Inst. 2002;94:981–990
  2. Christiansen CL, Wang F, Barton MB, et al.  Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst. 2000;92:1657–1666
  3. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276:1309–1315
  4. Etzioni R, Legler JM, Feuer EJ, et al: Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91: 1033–1039, 1999

PII: S0090-4295(02)02157-X

Urology
Volume 61, Issue 1 , Pages 5-6 , January 2003

Article Tools